AVROBIO News Releases http://investors.avrobio.com/ AVROBIO News Releases en AVROBIO, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-reports-first-quarter-2019-financial-results-and Regulatory clearances achieved that enable integration of the plato™ platform into Fabry FAB-201 and Gaucher GAU-201 clinical trials in the second half of 2019 IND for AVR-RD-01 for the treatment of Fabry disease cleared by the FDA ; AVROBIO plans to open U.S. Mon, 13 May 2019 07:00:00 -0400 AVROBIO News Releases 6956 AVROBIO, Inc. Announces FDA Clearance of Investigational New Drug Application for AVR-RD-01 Gene Therapy for the Treatment of Fabry Disease http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-announces-fda-clearance-investigational-new-drug The plato™ platform represents a significant advance towards a commercial-stage gene therapy solution designed to treat thousands of patients AVROBIO to incorporate U.S. clinical sites into its ongoing global FAB-201 Phase 2 clinical trial in Fabry disease CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. Mon, 29 Apr 2019 07:00:00 -0400 AVROBIO News Releases 6946 AVROBIO Highlights the plato™ Platform and Gaucher and Cystinosis Programs at the 2019 Annual Meeting of the American Society of Gene and Cell Therapy http://investors.avrobio.com/news-releases/news-release-details/avrobio-highlights-platotm-platform-and-gaucher-and-cystinosis CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 26, 2019-- AVROBIO, Inc. (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced the participation of its senior management in sessions at the Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). Fri, 26 Apr 2019 16:00:00 -0400 AVROBIO News Releases 6941 AVROBIO, Inc. Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-reports-fourth-quarter-and-fiscal-year-2018 Recruitment completed in investigator-sponsored Phase 1 Fabry study Phase 1 and Phase 2 clinical data updates for AVR-RD-01 in Fabry disease reported at WORLDSymposium 2019 Clinical trials in Gaucher and cystinosis expected to start in 2019 Introduced plato™ platform for worldwide gene therapy Mon, 25 Mar 2019 07:00:00 -0400 AVROBIO News Releases 6891 AVROBIO, Inc. to Present at the Cowen and Company 39th Annual Health Care Conference http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-present-cowen-and-company-39th-annual-health-care CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2019-- AVROBIO, Inc . (NASDAQ:AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that the Company will present at the Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 , at 8:40 a.m. Tue, 05 Mar 2019 07:00:00 -0500 AVROBIO News Releases 6871 AVROBIO, Inc. Announces Updated Clinical Data from Ongoing Phase 1 and Phase 2 Studies for AVR-RD-01 Gene Therapy for Fabry Disease http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-announces-updated-clinical-data-ongoing-phase-1-and All patients with reported data exhibit AGA enzyme activity above the diagnostic range for males with classic Fabry disease after receiving AVR-RD-01, including at 22 months for Patient 1 in the Phase 1 study Impact of gene therapy on substrate and metabolite levels observed both in patients who Wed, 06 Feb 2019 09:00:00 -0500 AVROBIO News Releases 6821 AVROBIO, Inc. Announces Time Change for Analyst and Investor Presentation and Webcast, now 5:30 p.m. ET on Wednesday, February 6, 2019 http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-announces-time-change-analyst-and-investor CAMBRIDGE, Mass. , Feb. 01, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced a time change for its analyst and investor presentation and webcast scheduled for Wednesday, February 6, 2019 , at which time the Fri, 01 Feb 2019 07:00:00 -0500 AVROBIO News Releases 6811 AVROBIO, Inc. Announces Acceptance of Investigational New Drug (IND) Application for Investigator-Sponsored Phase 1/2 Clinical Trial for AVR-RD-04 Gene Therapy for Cystinosis http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-announces-acceptance-investigational-new-drug-ind Phase 1/2 study to be led by team at University of California, San Diego, with rights licensed to AVROBIO CAMBRIDGE, Mass. , Jan. 18, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene Fri, 18 Jan 2019 07:00:00 -0500 AVROBIO News Releases 6781 AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019 http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-announces-analyst-and-investor-event-and-upcoming Analyst and Investor Event to be Webcast on Wednesday, February 6, 2019 at 5:30 p.m. ET CAMBRIDGE, Mass. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene therapy company, today announced that clinical trial updates related to the Thu, 17 Jan 2019 07:00:00 -0500 AVROBIO News Releases 6776 AVROBIO, Inc. Appoints Philip J. Vickers to its Board of Directors http://investors.avrobio.com/news-releases/news-release-details/avrobio-inc-appoints-philip-j-vickers-its-board-directors Industry leader brings global expertise, including as Shire’s former Global Head of Research and Development, to help further accelerate momentum and growth CAMBRIDGE, Mass. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a clinical-stage gene therapy company, Mon, 07 Jan 2019 07:06:00 -0500 AVROBIO News Releases 6736